Literature DB >> 17405836

Tripartite control of growth hormone secretion in women during controlled estradiol repletion.

Johannes D Veldhuis1, Mihaela Cosma, Dana Erickson, Remberto Paulo, Kristi Mielke, Leon S Farhy, Cyril Y Bowers.   

Abstract

CONTEXT: Studies of how aging attenuates GH secretion are confounded by differences in sex-steroid milieus, abdominal visceral fat mass (AVF), and IGF-I concentrations and limited in interpretability by the use of pharmacological doses of secretagogues. HYPOTHESIS: In a controlled estrogenic milieu, near-physiological secretagogue drive will unmask distinct influences of age, AVF, and IGF-I on GH secretion. LOCATION: The study was conducted at an academic medical center.
SUBJECTS: Subjects included 10 healthy pre- (PRE) and 10 postmenopausal (POST) women. PROCEDURE: In a defined estradiol (E(2)) milieu, we compared GH secretion after submaximal stimulation with GH-releasing peptide (GHRP)-2 (ghrelin analog), GHRH, and l-arginine (an inhibitor of somatostatin outflow). ANALYSIS: We related GH responses to age stratum (dichotomous variable) and AVF and IGF-I concentrations (continuous variables).
RESULTS: In the face of comparable concentrations of E(2), testosterone, and SHBG: 1) age (P < 0.001) and secretagogue type (P < 0.001) independently determined GH secretion; 2) GH responses in POST subjects were only 26-33% of those in PRE (P < or = 0.002) across all secretagogues; 3) POST women lost the PRE order of secretagogue potency (GHRP-2 > GHRH = l-arginine); and 4) in the combined cohorts, higher AVF predicted reduced l-arginine-stimulated GH secretion (R(2) = 0.46, P = 0.0013), whereas higher IGF-I concentrations forecast increased GHRP-2 and GHRH drive (R(2) > or = 0.52, P < or = 0.013).
CONCLUSION: A paradigm of near-physiological secretagogue drive in an E(2)-clamped milieu unmasks tripartite deficits in peptide-signaling pathways in healthy POST, compared with PRE, women. Post hoc analyses indicate that both greater visceral adiposity and lower IGF-I concentrations mark this triple regulatory defect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17405836     DOI: 10.1210/jc.2007-0043

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.

Authors:  Shobhit Jain; Ninad Desai; Amrit Bhangoo
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 2.  Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women.

Authors:  Johannes D Veldhuis
Journal:  Ageing Res Rev       Date:  2008-01-05       Impact factor: 10.895

3.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

4.  Growth hormone response to submaximal doses of ghrelin remains unchanged during the follicular phase of the cycle.

Authors:  Christina I Messini; Konstantinos Dafopoulos; Maria Malandri; Panagiotis Georgoulias; George Anifandis; Ioannis E Messinis
Journal:  Reprod Biol Endocrinol       Date:  2013-05-10       Impact factor: 5.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.